uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a 15% YoY revenue increase and reduced net loss, the earnings call highlighted significant risks, including regulatory challenges and economic uncertainties, which may offset the positive financial performance. No new partnerships or shareholder return plans were discussed, and the strategic initiatives were unclear. The Q&A provided no additional insights to alter this neutral outlook.
Key Financial Performance
Revenue uniQure reported revenue of $52.3 million for Q1 2026, which represents a 15% increase year-over-year. This growth was primarily driven by higher product sales and increased collaboration revenue.
Net Loss The company reported a net loss of $18.7 million for Q1 2026, compared to a net loss of $22.5 million in Q1 2025. This improvement was attributed to higher revenue and cost management initiatives.
Research and Development Expenses R&D expenses were $30.2 million in Q1 2026, up 10% year-over-year. The increase was due to expanded clinical trial activities and investments in pipeline development.
General and Administrative Expenses G&A expenses were $12.5 million in Q1 2026, reflecting a 5% increase year-over-year. This was mainly due to higher personnel costs and professional fees.
Cash and Cash Equivalents uniQure ended Q1 2026 with $450 million in cash and cash equivalents, compared to $470 million at the end of Q4 2025. The decrease was due to operational expenses and investments in growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company may face challenges in obtaining necessary regulatory approvals for its products, which could delay product launches and impact financial performance.
Market Conditions: Adverse market conditions could affect the company's sales and revenue growth, particularly if there is a downturn in the healthcare sector.
Supply Chain Disruptions: Potential disruptions in the supply chain could impact the company's ability to manufacture and deliver products on time, affecting customer satisfaction and financial results.
Economic Uncertainties: Economic uncertainties, such as inflation or changes in currency exchange rates, could impact the company's operational costs and profitability.
Strategic Execution Risks: Challenges in executing strategic initiatives, such as mergers or acquisitions, could affect the company's growth prospects and market position.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bank PLC
Barclays Bank
Capital Markets
Chardan Capital
Chief Customer
Christian Klemt
Co
Customer Officer
Daniil Gataulin
Director Kylie
Division Daniil
Division Eliana
Division Guofang
Division Kristen
Division Luca
Division Patrick
Division Salveen
Division Suzanne
EDT Schwartz
Eliana Merle
Gataulin Chardan
Guofang Li
Klemt CFO
Kluska Cantor
Kristen Kluska
Kylie OKeefe
LLC Research
LLC name
Li Wolfe
Markets LLC
Merle Barclays
Research Division
QURE Transcript
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Unknown5-5
Despite a 15% YoY revenue increase and reduced net loss, the earnings call highlighted significant risks, including regulatory challenges and economic uncertainties, which may offset the positive financial performance. No new partnerships or shareholder return plans were discussed, and the strategic initiatives were unclear. The Q&A provided no additional insights to alter this neutral outlook.
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Unknown3-2
The earnings call reveals a mixed outlook. Financial health shows increased cash reserves due to public offerings, but expenses have risen. Product updates include progress in trials but also a pause due to adverse events. The Q&A highlights regulatory challenges and uncertainties in trial designs. While there is potential for market expansion, lack of clear guidance and unresolved FDA concerns temper optimism. Overall, the sentiment remains neutral due to mixed signals from financial health and regulatory hurdles.
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call summary shows mixed signals. The basic financial performance is weak due to a significant revenue decline, but the company maintains a strong cash position. Product development is promising with advanced pipeline stages and FDA breakthrough designation. Market strategy and shareholder return plans are unclear or not emphasized. The Q&A reveals optimism in regulatory and commercial prospects but lacks clarity on key metrics like NfL. Given these mixed factors, the stock is likely to remain stable in the short term, leading to a neutral prediction.
QURE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
